It leads to high blood sugar levels that can increase the risk of heart or kidney disease and nerve or vision damage
showed less pain, lower inflammation (CRP), and better cholesterol and blood pressure
US Food and Drug Administration (FDA) Approvals of GLP-1 and GLP1/GIP RAs 11,22-34 However, these labels are being expanded to include additional indications for patients with a spectrum of other cardiometabolic conditions, such as obesity, cardiovascular disease, chronic kidney disease, and obstructive sleep apnea
In a population without specific risk factors for thyroid cancer, the benefits of GLP-1 RAs will largely outweigh the harm. The European Medicines Agency in October 2023 announced that they did not find a causal link between GLP-1s and thyroid cancer after a months-long review
[17] Gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), has been observed with incretin-based therapies
Another option is new pills to treat obesity, which will be cheaper than their injectable counterparts
